Download PDF
Semin Thromb Hemost 2002; 28(2): 173-190
DOI: 10.1055/s-2002-27820
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Laboratory Diagnosis of Congenital von Willebrand Disease

Ulrich Budde1 , Elke Drewke1 , Kerstin Mainusch1 , Reinhard Schneppenheim2
  • 1Coagulation Laboratory, Laboratory Association Prof. Arndt and Partners, Hamburg
  • 2Department of Hematology, Children's Hospital, University Clinic, Hamburg, Germany
Further Information

Publication History

Publication Date:
03 May 2002 (online)

    Permissions and Reprints

ABSTRACT

Von Willebrand disease (vWD) is caused by quantitative or qualitative defects, or both, of the von Willebrand factor (vWF), a multimeric high-molecular glycoprotein (GP). Typically, it affects the primary hemostatic system, which is reflected by a mucocutaneous bleeding tendency simulating a platelet function defect. The vWF promotes its function in two ways: (1) by supporting platelet adhesion to the injured vessel wall under conditions of high shear forces and (2) by its carrier function for factor VIIIc (FVIIIc) in plasma. Because of the complexity of the disease, diagnosis of vWD is one of the most challenging of any coagulation disorder. The stepwise diagnosis of vWD includes patients and family history, screening procedures (bleeding time [BT], filter tests, platelet counts, activated partial thromboplastin time [aPTT]), confirmatory tests (vWF antigen [vWF:Ag], vWF ristocetin cofactor activity [vWF:RCo], vWF collagen-binding [vWF:CB] assay, ristocetin-induced platelet aggregation [RIPA], FVIIIc) and tests for final classification (multimeric analysis, FVIII binding capacity of vWF [vWF:FVIIIB], platelet vWF). In 1999, we classified 303 patients with congenital vWD as type 1 (n = 122), type 2 (n = 171), and type 3 (n = 10). Type 2 was further subdivided into type 2A (n = 126), type 2B (n = 17), type 2M (n = 22), and type 2N (n = 6). Type 2A showed a remarkable heterogeneity, with only 27.8% (n = 36) of the ``classic'' IIA pattern. The other high-frequency patterns were type IB (25.4% n = 32) and type IIE/F/H-like structural abnormalities (28.6% n = 36). The spectrum was completed with samples from patients with types 2D, 2C, 2C Miami, smeary structures, and other rare subtypes (together 18.9% n = 23).

KEYWORDS

vWD - von Willebrand factor - classification - ristocetin cofactor assay - von Willebrand collagen binding capacity assay - vWF multimers - standardization

REFERENCES

  • 1 Sadler J E, Mannucci P M, Berntorp E. Impact, diagnosis and treatment of von Willebrand disease.  Thromb Haemost . 2000;  84 160-174
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Ruggeri Z M. Structure and function of von Willebrand factor.  Thromb Haemost . 1999;  82 576-584
    PubMedGoogle Scholar
  • 3 Schneppenheim R, Thomas K B, Sutor A H. Von Willebrand disease in childhood.  Semin Thromb Haemost . 1995;  21 261-275
    PubMedGoogle Scholar
  • 4 von Willebrand A E. Hereditär pseudohemofili.  Finska Läk Sällsk Handl . 1926;  68 87-112
    PubMedGoogle Scholar
  • 5 Nilsson I M. Von Willebrand's disease from 1926-1983.  Scand J Haematol . 1984;  33(Suppl 40) 21-43
    PubMedGoogle Scholar
  • 6 Mancuso D J, Tuley E A, Westfield L A. Structure of the gene for human von Willebrand factor.  J Biol Chem . 1989;  264 19514-19527
    PubMedGoogle Scholar
  • 7 Furlan M, Robles R, Solenthaler M, Lämmle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura.  Blood . 1997;  91 3097-3103
    PubMedGoogle Scholar
  • 8 Ruggeri Z M, Zimmerman T S. Von Willebrand factor and von Willebrand disease.  Blood . 1987;  70 895-904
    PubMedGoogle Scholar
  • 9 Sadler E J. A revised classification of von Willebrand disease.  Thromb Haemost . 1994;  71 520-525
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Sadler E J, Gralnick H R. Commentary: A new classification for von Willebrand disease.  Blood . 1994;  84 676-679
    PubMedGoogle Scholar
  • 11 Nishino M, Girma J P, Rothschild C, Fressinaud E, Meyer D. New variant of von Willebrand disease with defective binding to factor VIII.  Blood . 1989;  74 1591-1599
    PubMedGoogle Scholar
  • 12 Mazurier C. Von Willebrand disease masquerading as haemophilia A.  Thromb Haemost . 1992;  67 391-396
    PubMedGoogle Scholar
  • 13 Schneppenheim R, Budde U, Ruggeri Z M. A molecular approach to the classification of von Willebrand disease.  Baillieres Clin Haematol . 2001;  14 281-298
    PubMedGoogle Scholar
  • 14 Rodeghiero F, Castaman G C, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease.  Blood . 1987;  69 454-459
    PubMedGoogle Scholar
  • 15 Miller C H, Lenzi R, Breen C. Prevalence of von Willebrand's disease among US adults.  Blood . 1987;  70 377-383
    PubMedGoogle Scholar
  • 16 Werner E J, Emmett H, Tucker E. Prevalence of von Willebrand disease in children. A multiethnic study.  J Pediatr . 1993;  123 893-898
    CrossrefPubMedGoogle Scholar
  • 17 Holmberg L, Nilsson I M. Von Willebrand's disease.  Clin Hematol . 1985;  14 461-488
    PubMedGoogle Scholar
  • 18 Vlot A J, Mauser Bunschoten P E, Zarkova A G. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A.  Thromb Haemost . 2000;  83 65-69
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Oerstavik K H, Kornstad L, Reisner H, Berg K. Possible effect of secretor locus on plasma concentration of factor VIII and von Willebrand factor.  Blood . 1989;  73 990-993
    PubMedGoogle Scholar
  • 20 Gill J C, Endres-Brooks J, Bauer P J, Marks W J, Montgomery R R. The effect of ABO blood group on the diagnosis of von Willebrand disease.  Blood . 1987;  69 1691-1695
    CrossrefPubMedGoogle Scholar
  • 21 Pottinger B E, Read R C, Paleolog E M, Higgins P C, Pearson J D. Von Willebrand factor is an acute phase reactant in man.  Thromb Res . 1989;  53 387-395
    CrossrefPubMedGoogle Scholar
  • 22 Sixma J J, de Groot G P. Von Willebrand factor and the blood vessel wall.  Mayo Clin Proc . 1991;  66 623-628
    PubMedGoogle Scholar
  • 23 Rodeghiero F, Castaman G, Ruggeri M, Tosetto A. The bleeding time in normal subjects is mainly determined by platelet von Willebrand factor and is independent from blood group.  Thromb Res . 1992;  65 605-615
    CrossrefPubMedGoogle Scholar
  • 24 DiPaola J, Federici A B, Mannucci P M. Low platelet alpha(2)beta(1) levels in type 1 von Willebrand disease correlate with impaired platelet function in a high shear stress system.  Blood . 1999;  93 3578-3582
    PubMedGoogle Scholar
  • 25 Lind S E. The bleeding time does not predict surgical bleeding.  Blood . 1991;  77 2547-2552
    CrossrefPubMedGoogle Scholar
  • 26 Duke W W. The relation of blood platelets to hemorrhagic disease.  JAMA . 1910;  55 1185-1192
    CrossrefPubMedGoogle Scholar
  • 27 Ivy A C, Shapiro P F, Melnick P. The bleeding tendency in jaundice.  Surg Gynecol Obstet . 1935;  60 781-784
    PubMedGoogle Scholar
  • 28 Mielke C H. Influence of aspirin on platelets and the bleeding time.  Am J Med . 1983;  74 72-78
    CrossrefPubMedGoogle Scholar
  • 29 Sramek R, Sramek A, Koster T, Briet E, Rosendaal F R. A randomized and blinded comparison of 3 bleeding time techniques-The Ivy method, and the Simplate-II℗ method in 2 directions.  Thromb Haemost . 1992;  67 514-518
    PubMedGoogle Scholar
  • 30 Kratzer M AA, Born G VR. Simulation of primary hemostasis in vitro.  Haemostasis . 1985;  15 357-362
    PubMedGoogle Scholar
  • 31 Weippert-Kretschmer M, Witte M, Budde U. The Thrombostat 4000. A sensitive screening test for von Willebrand's disease.  Semin Thromb Haemost . 1995;  21(Suppl 2) 44-51
    PubMedGoogle Scholar
  • 32 Fressinaud E, Veyradier A, Truchaud F. Screening for von Willebrand disease with a new analyzer using high shear stress: A study of 60 cases.  Blood . 1998;  91 1232-1231
    PubMedGoogle Scholar
  • 33 O'Brien J R, Salmon G P. Shear stress activation of platelet glycoprotein IIb/IIIa plus von Willebrand factor causes aggregation: filter blockage and the long term bleeding time in von Willebrand's disease.  Blood . 1987;  70 1354-1361
    PubMedGoogle Scholar
  • 34 Schlammadinger A, Kerenyi A, Muszbek L, Boda Z. Comparison of the O'Brien filter test and the PFA-100 platelet analyzer in the laboratory diagnosis of von Willebrand's disease.  Thromb Haemost . 2000;  84 88-92
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Dean J A, Blanchette V S, Carcao M D. von Willebrand disease in a pediatric based population-Comparison of type 1 diagnostic criteria and use of the PFA-100℗ and a von Willebrand factor/collagen-binding assay.  Thromb Haemost . 2000;  84 401-409
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 Cramer A D, Melaragne A J, Phifer S J, Hougie C. Von Willebrand disease San Diego, a new variant.  Lancet . 1976;  ii 122
    PubMedGoogle Scholar
  • 37 Bux-Gewehr I, Morgenschweis K, Zotz R B, Budde U, Scharf R. Combined von Willebrand factor deficiency and factor XII deficiency.  Thromb Haemost . 2000;  83 514-516
    PubMedGoogle Scholar
  • 38 Baumgartner H R, Tschopp T B, Meyer D. Shear rate dependent inhibition of platelet adhesion and aggregation on collagenous surfaces by antibodies to human factor VIII/von Willebrand factor.  Br J Haematol . 1980;  44 127-139
    CrossrefPubMedGoogle Scholar
  • 39 Sakariassen K S, Nieuwenhuis K, Sixma J J. Differentiation of patients with subtype IIb-like von Willebrand's disease by means of perfusion experiments with reconstituted blood.  Br J Haematol . 1985;  59 459-470
    PubMedGoogle Scholar
  • 40 Varon D, Lashevski I, Brenner B. Cone and plate(let) analyzer: monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions.  Am Heart J . 1998;  135(Suppl) S187-S193
    PubMedGoogle Scholar
  • 41 Hellem A J. Platelet adhesiveness in von Willebrand's disease. A study with a new modification of the glass bead filter method.  Scand J Haematol . 1970;  7 374-382
    PubMedGoogle Scholar
  • 42 Salzman E W. Measurement of platelet adhesiveness. A simple in vitro technique demonstrating an abnormality in von Willebrand's disease.  J Lab Clin Med . 1983;  62 724-735
    PubMedGoogle Scholar
  • 43 Hubbard A R, Rigsby P, Barrowcliffe T W. Standardisation of factor VIII and von Willebrand factor in plasma: Calibration of the 4th International Standard (97/586).  Thromb Haemost . 2001;  85 634-638
    PubMedGoogle Scholar
  • 44 Nitu-Whalley H IC, Lee C A, Griffioen A, Jenkins P V, Pasi K J. Type 1 von Willebrand disease-a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history.  Br J Haematol . 2000;  108 259-264
    CrossrefPubMedGoogle Scholar
  • 45 Gralnick H R, Rick M E, McKeown L P. Platelet von Willebrand factor: an important determinant of the bleeding time in type I von Willebrand's disease.  Blood . 1986;  68 58-61
    PubMedGoogle Scholar
  • 46 Rodeghiero F, Castaman G C, Tosetto A, Lattuada A, Mannucci P M. Platelet von Willebrand factor assay-results using 2 methods for platelet lysis.  Thromb Res . 1990;  59 259-267
    CrossrefPubMedGoogle Scholar
  • 47 Zimmerman T S, Hoyer L W, Dickinson, Edgington T S. Determination of the von Willebrand's disease antigen (factor VIII-related antigen) in plasma by immunoelectrophoresis.  J Lab Clin Med . 1975;  86 152-159
    PubMedGoogle Scholar
  • 48 Cejka J. Enzyme immunoassay for factor VIII-related antigen.  Clin Chem . 1992;  28 1356-1358
    PubMedGoogle Scholar
  • 49 Veyradier A, Fressinaud E, Sigaud M, Wolf M, Meyer D. A new automated method for von Willebrand factor antigen measurement using latex particles.  Thromb Haemost . 1999;  81 320-321
    PubMedGoogle Scholar
  • 50 Weiss H J, Hoyer L W, Rickles F, Varma A, Rogers J. Quantitative assay of a plasma factor in von Willebrand's disease that is necessary for platelet aggregation.  J Clin Invest . 1973;  52 2701-2716
    PubMedGoogle Scholar
  • 51 Macfarlane D E, Stibbe J, Kirby E P. A method for assaying von Willebrand factor (ristocetin cofactor).  Thrombosis et Diathesis Haemorrhagica . 1975;  34 306-308
    PubMedGoogle Scholar
  • 52 Brinkhous K M, Graham J E, Cooper H A, Allain J P, Wagner R H. Assay of von Willebrand factor in von Willebrand's disease and hemophilia: use of a macroscopic platelet aggregation test.  Thromb Res . 1975;  6 267-272
    CrossrefPubMedGoogle Scholar
  • 53 Brinkhous K M, Read M S. Preservation of platelet receptors for platelet aggregation factor/von Willebrand factor by air drying, freezing or lyophilization: new stable platelet preparations for von Willebrand factor assays.  Thromb Res . 1987;  13 591-595
    PubMedGoogle Scholar
  • 54 Favaloro E J, Smith J, Petinos P, Hertzberg H, Koutts J. on behalf of the RCPA Quality Assurance Program (QAP) in Haematology Haemostasis Advisory Panel. Laboratory testing for von Willebrand disease: an assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey.  Thromb Haemost . 1999;  82 1276-1282
    PubMedGoogle Scholar
  • 55 Vanhoorelbeke K, Cauwenbergs N, Vauterin S. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor.  Thromb Haemost . 2000;  83 107-113
    Article in Thieme ConnectPubMedGoogle Scholar
  • 56 Murdock P J, Woodhams B J, Matthews K B, Pasi J, Goodall A H. Von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin platelet agglutination assay for diagnostic use.  Thromb Haemost . 1997;  78 1272-1277
    Article in Thieme ConnectPubMedGoogle Scholar
  • 57 Preston F E. Assays for von Willebrand factor functional activity: a UK NEQAS survey.  Thromb Haemost (Letter) . 1998;  80 866
    PubMedGoogle Scholar
  • 58 Favaloro E. Collagen binding assay for von Willebrand factor (vWF:CBA): detection of von Willebrands disease (vWD), and discrimination of vWD subtypes, depends on collagen source.  Thromb Haemost . 2000;  83 127-135
    PubMedGoogle Scholar
  • 59 Nitu-Whalley I C, Ridell A, Lee C A. Identifications of type 2 von Willebrand disease in previously diagnosed type 1 patients: a reappraisal using phenotypes, genotypes and molecular modelling.  Thromb Haemost . 2000;  84 998-1004
    PubMedGoogle Scholar
  • 60 Favaloro E J. Detection of von Willebrand disorder and identification of qualitative von Willebrand factor defects. Direct comparison of commercial ELISA-based von Willebrand factor activity options.  Am J Clin Pathol . 2000;  114 608-618
    CrossrefPubMedGoogle Scholar
  • 61 Howard M A, Perkin J, Salem H H, Firkin B G. The agglutination of human platelets by bothrocetin: evidence that bothrocetin and ristocetin act at different sites on the factor VIII molecule and platelet membrane.  Br J Haematol . 1984;  57 25-35
    PubMedGoogle Scholar
  • 62 Fujimura Y, Miyata S, Nishida S. The interaction of bothrocetin with normal or variant von Willebrand factor (type-IIA and type-IIB) and its inhibition by monoclonal antibodies that block receptor binding.  Thromb Haemost . 1992;  68 464-469
    PubMedGoogle Scholar
  • 63 Brown J E, Bosak J O. An ELISA test for the binding of von Willebrand factor antigen to collagen.Thromb Res .  1986;  43 303-311
    CrossrefPubMedGoogle Scholar
  • 64 Thomas K B, Sutor A H, Zieger B. A simple test for the determination of the von Willebrand factor function: the collagen binding activity.  Hämostaseologie . 1994;  14 133-139
    PubMedGoogle Scholar
  • 65 Pietu G, Fressinaud E, Girma J P. Binding of human von Willebrand factor to collagen and to collagen-stimulated platelets.  J Lab Clin Med . 1987;  109 637-646
    PubMedGoogle Scholar
  • 66 Budde U, Schneppenheim R, Zieger B. CBA/vWF:Ag ratio for diagnosis of von Willebrand disease (vWD): incorrect classification in more than 10% of patients with vWD type 2.  Thromb Haemost (Abst) . 1999;  100 (Suppl)
    PubMedGoogle Scholar
  • 67 Favaloro E J, Dean M, Grispo L, Exner T, Koutts J. von Willebrand's disease: use of collagen binding assay provides potential improvement to laboratory monitoring of desmopressin (DDAVP) therapy.  Am J Hematol . 1994;  45 205-211
    CrossrefPubMedGoogle Scholar
  • 68 Kempfer A C, Silaf M R, Farias C E. Binding of von Willebrand factor to collagen by flow cytometry.  Am J Clin Pathol . 1999;  111 418-423
    CrossrefPubMedGoogle Scholar
  • 69 Howard M A, Firkin B G. Ristocetin-a new tool in the investigation of platelet aggregation.  Thrombosis et Diathesis Haemorrhagica . 1971;  26 362-369
    PubMedGoogle Scholar
  • 70 Ruggeri Z M, Pareti F I, Mannucci P M, Ciavarella N, Zimmerman T S. Hightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease.  N Engl J Med . 1980;  302 1047-1051
    CrossrefPubMedGoogle Scholar
  • 71 Weiss H J, Meyer D, Rabinowitz R. Pseudo-von Willebrand's disease: an intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers.  N Engl J Med . 1982;  307 326-333
    PubMedGoogle Scholar
  • 72 Hilbert L, Jenkins P V, Gaucher C. Type 2M vWD resulting from a lysine deletion within a four lysine residue repeat in the A1 loop of von Willebrand factor.  Thromb Haemost . 2000;  84 188-194
    PubMedGoogle Scholar
  • 73 De Marco L, Mazzuccato M, Del Ben G M. Type IIB von Willebrand factor with normal sialic acid content induces platelet aggregation in the absence of ristocetin.  J Clin Invest . 1987;  80 475-482
    PubMedGoogle Scholar
  • 74 van Genderen J J P, Leenknegt H. Normal binding of plasma von Willebrand factor to platelets in essential thrombocythemia.  Am J Hematol . 1999;  61 153-154
    CrossrefPubMedGoogle Scholar
  • 75 de Romeuf C, Mazurier C. Interest of a simple and fast method for platelet von Willebrand factor characterization.  Thromb Res . 1996;  15 287-298
    PubMedGoogle Scholar
  • 76 Vischer U M, Ingerslev J, Wollheim C B. Acute von Willebrand factor secretion from the endothelium in vivo: assessment through plasma propeptide (vWf:AgII) levels.  Thromb Haemost . 1997;  77 387-393
    PubMedGoogle Scholar
  • 77 de Romeuf C, Mazurier C. Comparison between von Willebrand factor (vWF) and vWF antigen II in normal individuals and patients with von Willebrand disease.  Thromb Haemost . 1998;  80 37-41
    PubMedGoogle Scholar
  • 78 van Genderen J J P, Boertjes R C, van Mourik A J. Quantitative analysis of von Willebrand factor and its propeptide in plasma in acquired von Willebrand syndrome.  Thromb Haemost . 1998;  80 495-498
    PubMedGoogle Scholar
  • 79 Peake I R, Bloom A L, Giddings J C. Inherited variants of factor VIII-related protein in von Willebrand's disease.  N Engl J Med . 1974;  291 113-117
    CrossrefPubMedGoogle Scholar
  • 80 Ruggeri Z M, Zimmerman T S. Variant von Willebrand's disease. Characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets.  J Clin Invest . 1980;  65 1318-1325
    CrossrefPubMedGoogle Scholar
  • 81 Hoyer L W, Shainoff J R. Factor VIII-related protein circulates in normal human plasma as high molecular weight multimers.  Blood . 1998;  55 1056-1059
    PubMedGoogle Scholar
  • 82 Dent J A, Galbusera M, Ruggeri Z M. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit.  J Clin Invest . 1991;  88 774-782
    CrossrefPubMedGoogle Scholar
  • 83 Budde U, Schneppenheim R, Plendl H. Luminographic detection of von Willebrand factor multimers in agarose gels and on nitrocellulose membranes.  Thromb Haemost . 1990;  63 312-315
    PubMedGoogle Scholar
  • 84 Enayat M S. Multimeric analysis of von Willebrand factor. In: Hemostasis and Thrombosis Protocols (Methods in Molecular Medicine Series) 1999 31: 187-200
    Google Scholar
  • 85 Aihara M, Sawada Y, Ueno K. Visualization of von Willebrand factor multimers by immunoenzymatic stain using avidin-biotin peroxidase complex.  Thromb Haemost . 1986;  55 263-267
    PubMedGoogle Scholar
  • 86 Bukh A, Ingerslev J, Stenbjerg S, Hundahl Möller P N. The multimeric structure of plasma FVIII:RAg studied by electroelution and immunoperoxidase detection.  Thromb Res . 1986;  43 579-584
    CrossrefPubMedGoogle Scholar
  • 87 Baillod P, Affolter B, Kurt G H, Pflugshaupt R. Multimeric analysis of von Willebrand factor by vertical sodium dodecyl sulphate agarose gel electrophoresis, vacuum blotting technology and sensitive visualization by alkaline phosphatase anti-alkaline phosphatase complex.  Thromb Res . 1992;  66 745-755
    CrossrefPubMedGoogle Scholar
  • 88 Schneppenheim R, Plendl H, Budde U. Luminography-an alternative assay for detection of von Willebrand factor multimers.  Thromb Haemost . 1988;  60 133-136
    PubMedGoogle Scholar
  • 89 Zimmerman T S, Dent J A, Ruggeri Z M, Nannini L H. Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID and IIE).  J Clin Invest . 1986;  77 947-951
    CrossrefPubMedGoogle Scholar
  • 90 Budde U, Scharf R, Hartmann-Budde K, Dent J, Ruggeri Z M. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma.  Blood . 1993;  82 1749-1757
    CrossrefPubMedGoogle Scholar
  • 91 Mannucci P M, Moia M, Rebulla P. Correction of the bleeding time in treated patients with von Willebrand disease is not solely dependent on the normal multimeric structure of plasma von Willebrand factor.  Am J Hematol . 1987;  25 55-65
    PubMedGoogle Scholar
  • 92 Mazurier C, Samor B, Goudemand M. Improved characterization of plasma von Willebrand factor heterogeneity when using 2.5% agarose gel electrophoresis.  Thromb Haemost . 1986;  55 61-69
    PubMedGoogle Scholar
  • 93 Jorieux S, Gaucher C, Goudemand J, Mazurier C. A novel mutation in the D3 domain of von Willebrand factor markedly decreases its abiliy to bind factor VIII and affects its multimerization.  Blood . 1998;  92 4463-4670
    PubMedGoogle Scholar
  • 94 Budde U, Dent J A, Berkowitz S D, Ruggeri Z M, Zimmerman T S. Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome.  Blood . 1986;  68 1213-1217
    PubMedGoogle Scholar
  • 95 Pareti F I, Lattuada A, Bressi C. Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis.  Circulation . 2000;  102 1290-1295
    CrossrefPubMedGoogle Scholar
  • 96 Lopez Fernandez F M, Blanco Lopez J M, Castineira M P, Batlle J. Further evidence for recessive inheritance of von Willebrand disease with abnormal binding of von Willebrand factor to factor VIII.  Am J Hematol . 1992;  40 20-27
    PubMedGoogle Scholar
  • 97 Schneppenheim R, Budde U, Krey S. Results of a screening for von Willebrand disease type 2N patients with suspected haemophilia A or von Willebrand disease type 1.  Thromb Haemost . 1996;  76 598-602
    PubMedGoogle Scholar
  • 98 Mazurier C, Meyer D. Factor VIII binding assay of von Willebrand factor and the diagnosis of type 2N von Willebrand disease-results of an international survey.  Thromb Haemost . 1996;  76 270-274
    Article in Thieme ConnectPubMedGoogle Scholar
  • 99 Mazurier C, Goudemand J, Hilbert L. Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology.  Baillieres Clin Haematol . 2001;  14 337-347
    PubMedGoogle Scholar
  • 100 Allen S, Abuzenadah A M, Blagg J L. A novel type 2N von Willebrand disease-causing mutation that results in defective factor VIII binding, multimerization, and secretion of von Willebrand factor.  Blood . 2000;  95 2000-2007
    PubMedGoogle Scholar
  • 101 Jorieux S, Fressinaud E, Goudemand J. Conformational changes in the D′ domain of von Willebrand factor induced by CYS25 and CYS95 mutations lead to factor VIII binding defect and multimeric impairment.  Blood . 2000;  95 3139-3145
    CrossrefPubMedGoogle Scholar
  • 102 Schneppenheim R, Obser T, Lenk H. Characterization of a combined defect of FVIII binding and multimerization in a patient with von Willebrand disease type 2N.  Blood (Abst) . 2000;  96 566a
    PubMedGoogle Scholar
  • 103 Schneppenheim R, Budde U, Obser T. Expression and characterization of von Willebrand dimerization defects in different types of von Willebrand disease.  Blood . 2001;  97 2059-2066
    CrossrefPubMedGoogle Scholar
  • 104 Gaucher C, Dieval J, Mazurier C. Characterization of von Willebrand factor gene defects in two unrelated patients with type IIC von Willebrand disease.  Blood . 1994;  84 1024-1030
    PubMedGoogle Scholar
  • 105 Schneppenheim R, Obser T, Schneppenheim S. Von Willebrand disease type 2A with aberrant structure of individual oligomers is caused by mutations clustering in the von Willebrand factor D3 domain.  Blood (Abst) . 2000;  96 566a
    PubMedGoogle Scholar
  • 106 Hilbert L, Jenkins P V, Gaucher C, Meriane E, Pasi J K, Mazurier C. Type 2M vWD resulting from a lysine deletion within a four lysine residue repeat in the A1 loop of von Willebrand factor.  Thromb Haemost . 2000;  84 188-194
    PubMedGoogle Scholar
  • 107 Casonato A, Pontara E, Sartorello F. Type 2M von Willebrand disease variant characterized by abnormal multimerization.  J Lab Clin Med . 2001;  137 70-76
    CrossrefPubMedGoogle Scholar
  • 108 Mannucci P M, Lombardi R, Bader R. Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor.  Blood . 1985;  66 796-802
    PubMedGoogle Scholar
  • 109 Hoyer L W, Rizza C R, Tuddenham E G. von Willebrand factor multimer patterns in von Willebrand's disease.  Br J Haematol . 1983;  55 493-507
    PubMedGoogle Scholar
  • 110 Weiss H J, Pietu G, Rabinowitz R. Heterogeneous abnormalities in the multimeric structure, antigenic properties, and plasma-platelet content of factor VIII/von Willebrand factor in subtypes of classic (type I) and variant (type IIA) von Willebrand's disease.  J Lab Clin Med . 1983;  10 411-425
    PubMedGoogle Scholar
  • 111 Ruggeri Z M, Nilsson I M, Lombardi R, Holmberg L, Zimmerman T S. Aberrant multimeric structure of von Willebrand factor in a new variant of von Willebrand's disease (type IIC).  J Clin Invest . 1982;  70 1124-1127
    PubMedGoogle Scholar
  • 112 Kinoshita S, Harrison J, Lazerson J, Abildgaard C F. A new variant of dominant type II von Willebrand's disease with aberrant multimeric pattern of factor VIII-related antigen (type IID).  Blood . 1984;  63 1369-1371
    PubMedGoogle Scholar
  • 113 Hill F G, Enayat M S, George A J. Investigation of a kindred with a new autosomal dominantly inherited variant type von Willebrand's disease (possible type IID).  J Clin Pathol . 1985;  38 665-670
    PubMedGoogle Scholar
  • 114 Mannucci P M, Lombardi R, Federici A B. A new variant of type II von Willebrand disease with aberrant multimeric structure of plasma but not platelet von Willebrand factor (type IIF).  Blood . 1986;  68 269-274
    PubMedGoogle Scholar
  • 115 Gralnick H R, Williams S B, McKeown L P. A variant of type II von Willebrand disease with an abnormal triplet structure and discordant effects of protease inhibitors on plasma and platelet von Willebrand factor structure.  Am J Hematol . 1987;  24 259-266
    PubMedGoogle Scholar
  • 116 Federici A B, Mannucci P M, Lombardi R. Type II H von Willebrand disease: new structural abnormality of plasma and platelet von Willebrand factor in a patient with prolonged bleeding time and borderline levels of ristocetin cofactor activity.  Am J Hematol . 1989;  32 287-293
    PubMedGoogle Scholar
  • 117 Castaman G, Rodeghiero F, Lattuada A, Mannucci P M. A new variant of von Willebrand disease (type II I) with a normal degree of proteolytic cleavage of von Willebrand factor.  Thromb Res . 1992;  65 343-351
    CrossrefPubMedGoogle Scholar
  • 118 Weiss H J, Sussman I I. A new von Willebrand variant (type I, New York): increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing the full range of multimers.  Blood . 1986;  68 149-156
    CrossrefPubMedGoogle Scholar
  • 119 Holmberg L, Berntorp E, Donner M, Nilsson I M. von Willebrand's disease characterized by increased ristocetin sensitivity and the presence of all von Willebrand factor multimers in plasma.  Blood . 1986;  68 668-672
    CrossrefPubMedGoogle Scholar
  • 120 Firkin B, Firkin F, Stott L. von Willebrand's disease type B: a newly defined bleeding diathesis.  Aust N Z J Med . 1973;  33 225-229
    PubMedGoogle Scholar
  • 121 Mannucci P M, Lombardi R, Castaman G. von Willebrand disease ``Vicenza'' with larger-than-normal (supranormal) von Willebrand factor multimers.  Blood . 1988;  71 65-70
    PubMedGoogle Scholar
  • 122 Ciavarella G, Ciavarella N, Antoncecchi S. High-resolution analysis of von Willebrand factor multimeric composition defines a new variant of type I von Willebrand disease with aberrant structure but presence of all size multimers (type IC).  Blood . 1985;  66 1423-1429
    PubMedGoogle Scholar
  • 123 Lopez-Fernandez M F, Gonzalez-Boullosa R, Blanco-Lopez M J, Perez M, Batlle J. Abnormal proteolytic degradation of von Willebrand factor after desmopressin infusion in a new subtype of von Willebrand disease (ID).  Am J Hematol . 1991;  36 163-170
    PubMedGoogle Scholar
  • 124 Zimmerman T S, Ruggeri Z M. von Willebrand's disease.  Prog Hemost Thromb . 1982;  6 203-236
    PubMedGoogle Scholar